Maiwei Biotech announced that it has signed a global strategic cooperation agreement with Sentonix, Inc., an emerging biotechnology company focused on providing precision therapies for neurodegenerative diseases. The two sides will focus on Parkinson's disease, Alzheimer's disease, and other neurodegenerative diseases, and jointly explore the early detection and clinical transformation of the next generation of innovative drugs. According to the agreement, in the future, the two sides will explore ways such as joint development, establishment of NewCo, and regional licensing to promote pipeline cooperation to achieve a seamless connection from project establishment to early detection to clinical transformation.

Zhitongcaijing · 6d ago
Maiwei Biotech announced that it has signed a global strategic cooperation agreement with Sentonix, Inc., an emerging biotechnology company focused on providing precision therapies for neurodegenerative diseases. The two sides will focus on Parkinson's disease, Alzheimer's disease, and other neurodegenerative diseases, and jointly explore the early detection and clinical transformation of the next generation of innovative drugs. According to the agreement, in the future, the two sides will explore ways such as joint development, establishment of NewCo, and regional licensing to promote pipeline cooperation to achieve a seamless connection from project establishment to early detection to clinical transformation.